Abstract:
:The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas. Patients with stable or progressive malignant primary glioma received erlotinib alone or combined with temozolomide in this dose-escalation study. In each treatment group, patients were stratified by coadministration of EIAEDs. Erlotinib was started at 100 mg orally once daily as a 28-day treatment cycle, with dose escalation by 50 mg/day up to 500 mg/day. Temozolomide was administered at 150 mg/m2 for five consecutive days every 28 days, with dose escalation up to 200 mg/m2 at the second cycle. Eightythree patients were evaluated. Rash, fatigue, and diarrhea were the most common adverse events and were generally mild to moderate. The recommended phase 2 dose of erlotinib is 200 mg/day for patients with glioblastoma multiforme who are not receiving an EIAED, 450 mg/day for those receiving temozolomide plus erlotinib with an EIAED, and at least 500 mg/day for those receiving erlotinib alone with an EIAED. Of the 57 patients evaluable for response, eight had a partial response (PR). Six of the 57 patients had a progression-free survival of longer than six months, including four patients with a PR. Coadministration of EIAEDs reduced exposure to erlotinib as compared with administration of erlotinib alone (33%-71% reduction). There was a modest pharmacokinetic interaction between erlotinib and temozolomide. The favorable tolerability profile and evidence of antitumor activity indicate that further investigation of erlotinib is warranted.
journal_name
Neuro Oncoljournal_title
Neuro-oncologyauthors
Prados MD,Lamborn KR,Chang S,Burton E,Butowski N,Malec M,Kapadia A,Rabbitt J,Page MS,Fedoroff A,Xie D,Kelley SKdoi
10.1215/S1522851705000451keywords:
subject
Has Abstractpub_date
2006-01-01 00:00:00pages
67-78issue
1eissn
1522-8517issn
1523-5866pii
8/1/67journal_volume
8pub_type
杂志文章相关文献
NEURO-ONCOLOGY文献大全abstract:BACKGROUND:A cDNA library made from 2 glioma cell lines, U87MG and T98G, was screened by serological identification of antigens by recombinant cDNA expression (SEREX) using serum from a glioblastoma patient. Elongation factor Tu GTP binding domain containing protein 1 (EFTUD1), which is required for ribosome biogenesis...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nou132
更新日期:2014-12-01 00:00:00
abstract::A phase I trial of an engineered poliovirus for the treatment of recurrent glioblastoma (GBM) has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36-month survival landmarks.1 Genetically engineered viruses (oncolytic viruses) have been in trials for GBM for almost two decades.2 These r...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/noy170
更新日期:2019-01-01 00:00:00
abstract::Paragangliomas are rare tumors of the paraganglia composed of specialized neural crest cells arising in association with sympathetic ganglia. Here we report a case of progressive, metastatic paraganglioma (glomus jugulare tumor) responsive to single agent gemcitabine. In addition, a brief review of chemotherapy for pa...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/2.3.190
更新日期:2000-07-01 00:00:00
abstract::The purpose of this study was to evaluate the activity of single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients with recurrent anaplastic glioma were treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations were repeated ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nor091
更新日期:2011-10-01 00:00:00
abstract::Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomiz...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/now182
更新日期:2016-10-01 00:00:00
abstract::Ependymal tumors are rare CNS tumors and may occur at any age, but their proportion among primary brain tumors is highest in children and young adults. Thus, the level of evidence of diagnostic and therapeutic interventions is higher in the pediatric compared with the adult patient population.The diagnosis and disease...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/nox166
更新日期:2018-03-27 00:00:00
abstract::In order to compare in vivo metabolism between malignant gliomas and normal brain, (13)C magnetic resonance (MR) spectroscopic imaging data were acquired from rats with human glioblastoma xenografts (U-251 MG and U-87 MG) and normal rats, following injection of hyperpolarized [1-(13)C]-pyruvate. The median signal-to-n...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nop043
更新日期:2010-02-01 00:00:00
abstract::In patients with parenchymal brain masses of uncertain origin responsive to corticosteroids, primary CNS lymphoma (PCNSL) should be considered. PCNSL is a rare but aggressive brain tumor that is highly sensitive to high-dose methotrexate (HDMTX)-based chemotherapy. We report a series of six patients with brain masses ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2006-037
更新日期:2007-04-01 00:00:00
abstract::Difficulties of drug delivery across the blood-brain barrier (BBB) and failure to eliminate cancer stem cells (CSCs) are believed to be the major causes of tumor recurrences in children with medulloblastoma (MB). Seneca Valley virus-001 (SVV-001) is a naturally occurring oncolytic picornavirus that can be systemically...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noq148
更新日期:2011-01-01 00:00:00
abstract:BACKGROUND:Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz215
更新日期:2020-04-15 00:00:00
abstract::Akt, one of the major downstream effectors of phosphatidylinositol 3-kinase, is hyper-expressed and activated in a variety of cancers including glioblastoma. However, the expression profiles of the Akt isoforms Akt1/PKBalpha, Akt2/PKBbeta, and Akt3/PKBgamma and their functional roles in malignant glioma are not well u...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nop026
更新日期:2010-03-01 00:00:00
abstract:BACKGROUND:Temozolomide (TMZ) resistance in Glioblastoma (GBM) is mediated by the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). MGMT promoter methylation (occurs in about 40% patients) is associated with loss of MGMT expression (MGMT-) that compromises DNA repair, leading to a favorable response to ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noab003
更新日期:2021-01-12 00:00:00
abstract:BACKGROUND:Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT. METHODS:Eligibility criteria included age ≥18 years, Karnofsky performance status ≥...
journal_title:Neuro-oncology
pub_type: 杂志文章,随机对照试验
doi:10.1093/neuonc/now007
更新日期:2016-06-01 00:00:00
abstract::Background Nuclear factor IA (NFIA), a transcription factor and essential regulator in embryonic glial development, is highly expressed in human glioblastoma (GBM) compared with normal brain, but its contribution to GBM and cancer pathogenesis is unknown. Here we demonstrate a novel role for NFIA in promoting growth a...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not167
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:The objective was to evaluate the risk and predictors of developing leptomeningeal disease (LMD) in patients with brain metastases treated with 5-fraction hypofractionated stereotactic radiotherapy (HSRT). METHODS:Patients treated with HSRT for intact brain metastases and/or surgical cavities were reviewed ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz144
更新日期:2020-01-11 00:00:00
abstract::Treatment for medulloblastoma during childhood impairs neurocognitive function in survivors. While those diagnosed at younger ages are most vulnerable, little is known about the long-term neurocognitive, functional, and physical outcomes in survivors as they approach middle age. In this retrospective cohort study, we ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nor015
更新日期:2011-05-01 00:00:00
abstract::Although external beam radiation is an essential component to the current standard treatment of primary brain tumors, its application is limited by toxicity at doses more than 80 Gy. Recent studies have suggested that brachytherapy with liposomally encapsulated radionuclides may be of benefit, and we have reported met...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nos060
更新日期:2012-04-01 00:00:00
abstract:Background:Glioblastoma (GBM) is one of the most common, aggressive, and invasive human brain tumors. There are few reliable mechanism-based therapeutic approaches for GBM patients. The transcriptional repressor RE1 silencing transcriptional factor (REST) regulates the oncogenic properties of a class of GBM stem-like c...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/now232
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:Assessment of treatment response by measuring tumor size is known to be a late and potentially confounded response index. Serial diffusion MRI has shown potential for allowing earlier and possibly more reliable response assessment in adult patients, with limited experience in clinical settings and in pediatr...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not034
更新日期:2013-08-01 00:00:00
abstract::Microglia, which contribute substantially to the tumor mass of glioblastoma, have been shown to play an important role in glioma growth and invasion. While a large number of experimental studies on functional attributes of microglia in glioma provide evidence for their tumor-supporting roles, there also exist hints in...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/nos116
更新日期:2012-08-01 00:00:00
abstract::The Atlas of Cancer Mortality in the United States, 1950-94 (Devesa et al.) published in 1999 by the National Institutes of Health suggests that there are elevated rates of brain and other nervous system cancer in the northwestern, north central, and southeastern parts of the country. Being descriptive in nature, the ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/S1152851703000450
更新日期:2004-07-01 00:00:00
abstract:BACKGROUND:Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymoma patients were restricted to small sample sizes, often with patients at a specific institution. METHODS:Clinically annotated ependymoma tissue samples from 19 institutions were centrally reviewed. Patients were all...
journal_title:Neuro-oncology
pub_type: 杂志文章,多中心研究
doi:10.1093/neuonc/nou162
更新日期:2015-03-01 00:00:00
abstract:BACKGROUND:Brain-derived neurotrophic factor (BDNF), a neurotrophin that regulates neuronal function and development, is implicated in several neurodegenerative conditions. Preliminary data suggest that a reduction of BDNF concentrations may lead to postchemotherapy cognitive impairment. We hypothesized that a single n...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov162
更新日期:2016-02-01 00:00:00
abstract::The exact incidence of pineal germ-cell tumors is largely unknown. The tumors are rare, and the number of patients with these tumors, as reported in clinical series, has been limited. The goal of this study was to describe pineal germ-cell tumors in a large number of patients, using data from available brain tumor dat...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2007-054
更新日期:2008-04-01 00:00:00
abstract:Background:Advances from glioma stemlike cell (GSC) research, though increasing our knowledge of glioblastoma (GBM) biology, do not influence clinical decisions yet. We explored the translational power of GSC-enriched cultures from patient-derived tumorspheres (TS) in predicting treatment response. Methods:The relatio...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/now304
更新日期:2017-08-01 00:00:00
abstract:BACKGROUND:Glioblastoma multiforme, a World Health Organization grade IV glioma, has a poor prognosis in humans despite current treatment options. Here, we present magnetic resonance imaging (MRI) data regarding the regression of aggressive rat F98 gliomas and human U87 glioma xenografts after treatment with the nitron...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nos337
更新日期:2013-03-01 00:00:00
abstract:Background:Arterial spin labeling is an MR imaging technique that measures cerebral blood flow (CBF) non-invasively. The aim of the study is to assess the diagnostic performance of arterial spin labeling (ASL) MR imaging for differentiation between high-grade glioma and low-grade glioma. Methods:Cochrane Library, Emba...
journal_title:Neuro-oncology
pub_type: 杂志文章,meta分析
doi:10.1093/neuonc/noy095
更新日期:2018-10-09 00:00:00
abstract::The homeobox transcription factor OTX2 plays an essential role during embryonic brain development. It is normally silenced in the adult brain, but is overexpressed by genomic amplification or other mechanisms in the majority of medulloblastomas (MBs). Retinoic acids (RAs) can suppress OTX2 expression and inhibit MB gr...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nop062
更新日期:2010-07-01 00:00:00
abstract:BACKGROUND:Accumulation and infiltration of microglia/brain macrophages around and into glioma tissue promote tumor invasion and expansion. One tumor-promoting mechanism of microglia/brain macrophages is upregulation of membrane type 1 matrix metalloprotease (MT1-MMP), which promotes the degradation of extracellular ma...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nou324
更新日期:2015-02-01 00:00:00
abstract::In photodynamic diagnosis, 5-aminolevulinic acid (5-ALA) is widely used for the fluorescence-guided resection of malignant brain tumors, where 5-ALA is converted to protoporphyrin IX, which exhibits strong fluorescence. Little is known, however, about the detailed molecular mechanisms underlying 5-ALA-induced fluoresc...
journal_title:Neuro-oncology
pub_type: 杂志文章,收录出版
doi:10.1093/neuonc/nor116
更新日期:2011-11-01 00:00:00